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OBJECTIVES: To measure healthcare costs for patients
receiving repaglinide, metformin, repaglinide/metformin,
and glyburide/metformin within a managed care organi-
zation (MCO). METHODS: Using retrospective phar-
macy and medical claims from a MCO, adult patients
with type 2 diabetes identiﬁed during CY2000 were strat-
iﬁed into the following cohorts based on their medication
regimen at identiﬁcation date: repaglinide only (n = 500),
metformin only (n = 26,535), repaglinide/metformin 
(n = 172), glyburide/metformin (n = 17,160). Pharmacy,
medical, and total (pharmacy + medical) healthcare costs
were measured for each cohort over a 9-month period.
Costs were adjusted for age, gender, and comorbidities
using Analysis of Covariance. RESULTS: Adjusted phar-
macy costs were lowest for patients receiving metformin
only ($1182; 95% CI $1172–$1191), followed by 
metformin/glyburide ($1339; 95% CI $1327–$1351),
repaglinide only ($1518; 95% CI $1447–$1588), and
repaglinide/metformin ($1936; 95% CI $1816–$2056).
Differences between the cohorts in adjusted medical 
and total healthcare costs were not statistically signiﬁ-
cant. Adjusted medical charges were $6988 for repaglin-
ide/metformin, $8236 for metformin/glyburide, $8267
for metformin only, and $10,392 for repaglinide only.
Total adjusted healthcare costs were lowest for repaglin-
ide/metformin ($8924), followed by metformin only
($9448), metformin/glyburide ($9576), and repaglinide
only ($11,910). CONCLUSIONS: Although not statisti-
cally signiﬁcant, repaglinide/metformin yielded lower
total healthcare costs than metformin alone, met-
formin/glyburide, or repaglinide alone. While these
results need to be conﬁrmed using larger patient popula-
tions, they imply that differences in pharmacy costs of
repaglinide/metformin therapy are offset by measurable
medical cost savings.
PDB22
THE DIRECT COST OF DIABETES TYPE 
2 IN POLAND—PRELIMINARY DATA FROM
CODIP STUDY
Kinalska IT1, Niewada MP2, Glogowski CA3,
Krzyzanowska AM3, Pietrasik A2, atek M4, Kamiñski B4,
Gierczynski JM3,Tomaszewski WW3
1Medical University of Bialystok, Poland, Bialystok, Poland;
2Medical University of Warsaw, Warsaw, Poland;
3GlaxoSmithKline Pharmaceuticals S.A, Warsaw, Poland;
4Warsaw School of Economics, Warsaw, Poland
L´
OBJECTIVES: Limited data are available on treatment
cost of diabetes Type 2 patients in Poland. The Cost 
Of Diabetes Type 2 In Poland (CODIP) is a multicenter,
bottom-up designed, retrospective study aimed at evalu-
ation of total cost of diabetes type 2 in Poland. Prelimi-
nary data on direct cost are presented. METHODS:
Patients diagnosed with type 2 diabetes mellitus were ran-
domly selected from outpatients’ charts databases and
surveyed with CODE-2 trial questionnaires adjusted to
Polish setting. Both patient and practitioner question-
naires collected data from each patient on: clinical char-
acteristic, medical and other resources used, quality of
life. Total treatment costs were calculated using drug
retail and medical procedures prices. Values are expressed
in USD value (PPP¢2001 1 PLN = 1,98). RESULTS: 303
patients from 24 centers were included. Mean age 61.0
(95% CI: 59.8; 62.2); time from diagnosis 10.9 (10.0;
11.7); 74.6% patients presented comorbidities with coro-
nary arteries disease as most prevalent (20.5%). The total
annual treatment costs amounted to 4390 PLN (2127
USD). The cost structure: 13.7% physicians consulta-
tions, 2.2% paramedics, 25.6% diabetic drug costs
(insulin 62.8%, oral hypoglycemic agents and glucagon
37.2%), hospital costs 35.7%, emergency service 0.6%.
CONCLUSIONS: Economic impact of diabetes Type 2 in
Poland is considerable. Insulin prescription patterns are
responsible for large part of drug costs.
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The NAVIGATOR trial will evaluate the impact of
nateglinide and valsartan on the progression to diabetes
in subjects with impaired glucose tolerance at risk for 
cardiovascular events. It is well documented that physi-
cian/site characteristics inﬂuence outcomes and resource
utilization in health economic analyses. However, these
characteristics are usually unknown in the international
clinical trial setting. OBJECTIVES: We developed an
approach to proﬁle investigators and sites in multina-
tional clinical trials by administering a survey during the
site recruitment phase of the NAVIGATOR trial. We
hypothesized that characteristics would vary geographi-
cally. METHODS: Survey items were developed based on
a literature review and clinicians’ input. Simple statistics
were used to describe the sample. ANOVA and c2 tests
were used to test for differences across geographic
regions. RESULTS: We received 528 investigator surveys
representing a response rate of 60% and 96% for US and
non-US countries, respectively. Eighty percent of investi-
gators were male and the mean age was 48 years. Forty
percent were endocrinologists, 39% internists, and 20%
